GSEA results showed that samples with deficiency of MTOR, CRISPLD2 or MORF4L1 showed consistent down-regulation in pathways of Alzheimer’s disease, Parkinson’s disease and Huntington’s disease (Figure 4F). This evidence concerns the gene CRISPLD2 and Alzheimer disease.